The Canada Gairdner International Award recognizes outstanding researchers whose unique scientific contributions have increased the understanding of human biology and disease and contributed to the relief of human suffering.

The Gairdner Foundation invites the scientific community to nominate qualified researchers for this Award.  Nominations in the field of translational research are welcome. The award is intended for seminal bodies of work, not cumulative lifetime achievement.

Quality nominations are essential to the evaluation process. Packages should be accurate, current, and complete throughout the five year period of consideration. The nomination portal is open each year from mid-April – October 1 for edits, changes or additions by nominators.

What is this prize?

The Killam Prizes are awarded to active Canadian scholars who have distinguished themselves through sustained excellence, making a significant impact in their respective fields in the humanities, social sciences, natural sciences, health sciences, and engineering.

Prize amount

Up to five prizes of $100,000 each (one prize per discipline)

How to qualify

Nominations must be submitted to the Council by an expert in the same field as the nominee.

A peer assessment committee will select the recipients from among all nominees.

Read the Killam Prizes Guidelines for eligibility criteria and the nomination form.

Visit the Killam Program website for more information on the Killam Prizes.

The FY20 Defense Appropriations Act provides funding to the Department of Defense Peer Reviewed Orthopaedic Research Program (PRORP) to support innovative, high-impact, clinically-relevant research to advance optimal treatment and rehabilitation from musculoskeletal injuries.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

The FY20 PRORP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

Applications submitted to the FY20 PRORP must address one or more of the following FY20 Focus Areas:

1.     Compartment Syndrome: Novel treatment strategies to improve current diagnoses for compartment syndrome. Alternatives to intracompartmental pressure measurements are encouraged.

2.     Limb Stabilization and Protection: Development and/or clinical assessment of rapid limb stabilization and novel wound protectants for severely wounded limbs to enable transport at the point of need.

3.     Orthotic Devices: Refinement of high-performance novel orthotic devices designed to enhance whole person performance and decrease pain in patients with limb salvage and impairment.

4.     Osseointegration: Identification of best practices to address infection, rejection, and/or failure of percutaneous osseointegrated prosthetic limbs.

5.     Retention Strategies: Development, optimization, and/or validation of battlefield-feasible diagnostic capabilities, decision support tools, interventions, and/or rehabilitation strategies that can facilitate retention on duty for common combat-related musculoskeletal injuries.  Biomarker studies are excluded.  The current standard of care must be noted.  The rehabilitation strategy and the standard of care must be specified, as applicable.

o   Point of Injury: Battlefield-feasible strategies that can be utilized at or near the point of injury to allow an injured Service member to remain on duty and stay on mission without the need for immediate evacuation.

o   Point of Duty: Strategies that can be utilized along the continuum of care to allow an injured Service member to return to duty without separation from Service.

6.     Tissue Regeneration Therapeutics: Development of advanced tissue regeneration therapeutics in nerve, muscle (to include volumetric muscle loss), and/or composite tissue for the restoration of traumatically injured extremities.  Isolated bone or cartilage tissue engineering studies are excluded.

7.     Translation of Early Findings: Translation of early research findings in the orthopaedic surgical care topic areas listed below to move the research toward clinical trials and clinical practice.

o   Soft Tissue Trauma: Strategies to develop and/or identify musculoskeletal extremity soft tissue trauma treatments for anterior cruciate ligament (ACL) or shoulder instability only, to optimize return to duty, work, or reintegration.

o   Fracture-Related Infection: Strategies to decrease the burden of fracture-related infections (may include prevention, early detection, or improved eradication).  Alternatives to systemic and/or local antibiotic delivery are encouraged. 

https://cdmrp.army.mil/funding/prorp

Applied Research Award – Preproposal due May 27, 2020

Independent investigators at all academic levels (or equivalent)

• Pre-application is required; full application submission is by invitation only.
• Supports applied research applications focused on advancing optimal treatment and restoration of function for individuals with musculoskeletal injuries sustained during combat or combat-related activities, and non-battle injuries that impact unit readiness and the ability to return to duty/work.
• Proposed research should be supported by preliminary data and have the potential to make significant advancements toward clinical translation.
• Clinical research and clinical trials are not allowed under this award mechanism.
• Applications must address one of the following FY20 PRORP Focus Areas:

o    Limb Stabilization and Protection

o    Retention Strategies

o    Point of Injury

o    Return to Duty

o    Osseointegration

• Maximum funding of $725,000 for total costs (includes direct and indirect costs).
• Maximum period of performance is 3 years.

Clinical Trial Award – Preproposal due May 27, 2020

Independent investigators at all academic levels (or equivalent)

• Pre-application is required; full application submission is by invitation only.
• Supports rapid implementation of clinical trials with the potential to have a major impact on military combat-related orthopaedic injuries or non-battle injuries that significantly impact unit readiness and return-to-duty/work rates.
• Funding must support a clinical trial and may not be used for preclinical research studies.
• Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration within 6 months of the award date.
  • ·      Applications must address one the following FY20 PRORP Focus Areas:

o    Limb Stabilization and Protection

o    Retention Strategies

o    Point of Injury

o    Return to Duty

o    Translation of Early Findings

o    Soft Tissue Trauma

o    Fracture-Related Infection

Funding Level 1:

• Maximum funding of $2.25M for total costs. (includes direct and indirect costs)
• Maximum period of performance is 4 years.

Funding Level 2:

(Translation of Early Findings – Soft Tissue Trauma Focus Area with Rehabilitation Option):

• Maximum funding of $2.75M for total costs (includes direct and indirect costs)
• Maximum period of performance is 4 years.

Clinical Translational Research Award – Preproposal is due May 27, 2020

Independent investigators at all academic levels (or equivalent)

• Pre-application is required; full application submission is by invitation only.
• Supports high-impact and/or new/emerging clinical research that may or may not be ready for a full-scale, randomized, controlled clinical trial.
• Funding must support clinical research studies involving humans.
• Preliminary or published data relevant to the proposed research project are required.
• ·      Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration within 12 months of the award date.
• ·      Applications must address one of the following FY19 PRORP CTRA Focus Areas:

o    Retention Strategies

o    Point of Injury

o    Return to Duty

o    Tissue Regeneration Therapeutics

o    Compartment Syndrome

o    Osseointegration

o    Orthotic Devices

• Maximum funding of $1.5M for total costs (including direct and indirect costs)
• Maximum period of performance is 4 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PRORP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507
help@eBrap.org

The FY20 Defense Appropriations Act provides funding to the Department of Defense Lung Cancer Research Program (LCRP) to support innovative, high-impact lung cancer research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

The FY20 LCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

Applications submitted to the FY20 LCRP must address one or more of the following Areas of Emphasis:

*Identify innovative strategies for the screening and early detection of lung cancer.

*Understand the molecular mechanisms of initiation and progression to lung cancer.

*Identify innovative strategies for prevention of the occurrence of lung cancer.

*Identify innovative strategies for the treatment of lung cancer.

*Identify innovative strategies for the prevention of recurrence of or metastases from lung cancer.

*Develop or optimize prognostic or predictive markers to assist with therapeutic decision-making.

*Understand mechanisms of resistance to treatment (primary and secondary).

*Understand contributors to lung cancer development other than tobacco.

*Identify innovative strategies for lung cancer care delivery (disparities/clinical management/ surveillance/symptom management).

Relevance to Military Health: The LCRP seeks to support research that is relevant to the healthcare needs of military Service members, Veterans, and their families. Relevance to military health will be considered in determining relevance to the mission of the DHP and FY20 LCRP during programmatic review.   Investigators are strongly encouraged to consider the following characteristics as examples of how a project may demonstrate relevance to military health:

*Use of military or Veteran populations, biospecimens, data/databases, or programs in the proposed research

*Collaboration with Department of Defense or Department of Veterans Affairs (VA) investigators

*Description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to address a military need that also benefits the civilian population

*Explanation of how the project addresses an aspect of lung cancer that has direct relevance to military Service members, Veterans, or other military health system beneficiaries, including environmental exposures other than tobacco

https://cdmrp.army.mil/funding/lcrp

Concept Award – Letter of Intent due May 27, 2020

Investigators at all academic levels

• Supports highly innovative, untested, potentially groundbreaking concepts in lung cancer.
• Emphasis on innovation.
• Clinical trials not allowed.
• Preliminary data discouraged.
• Relevance to military health strongly encouraged.
• Maximum funding of $100,000 in direct costs (plus indirect costs).
• Period of performance should not exceed 1 year.

Idea Development Award – Preproposal due May 6, 2020

Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent); or

New Investigators:  Investigators that meet the following criteria by the application submission deadline date:

• Have not previously received a LCRP Idea Development Award or Early Investigator Synergistic Idea Award
• Are within 10 years of first faculty appointment (or equivalent)
• Supports new ideas in the early stages of development representing innovative, high-risk/high-gain research.
• Emphasis on innovation and impact.
• New Investigator category supports applicants early in their faculty appointments or in the process of developing independent research careers.
• Clinical trials not allowed.
• Preliminary data required.
• Relevance to military health strongly encouraged.
• Maximum funding of $350,000 in direct costs (plus indirect costs).
• Period of performance should not exceed 2 years.

Investigator-Initiated Translational Research Award - Preproposal due May 6, 2020

Independent investigators at or above the level of Assistant Professor (or equivalent)

*Supports translational research that will develop promising ideas in lung cancer into clinical applications.  Translational research may be defined as an integration of basic science and clinical observations.

• This mechanism is intended to fund a broad range of translational studies including, but not limited to, the following:
• Studies advancing/translating in vitro and/or animal studies to applications with human samples/cohorts
• Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug submission
• Correlative studies that are associated with an ongoing or completed clinical trial and projects that develop endpoints for clinical trials
• Preliminary data required.
• Relevance to military health strongly encouraged.
• Maximum funding of $400,000 in direct costs (plus indirect costs).
• Period of performance should not exceed 2 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the LCRP or other CDMRP-administered programs, please visit the CDMRP website.

Point of Contact:

CDMRP Help Desk

301-682-5507

help@eBrap.org

Department of Defense Military Burn Research Program
Funding Opportunities for Fiscal Year 2020 (FY20)

The FY20 Defense Appropriation Act provides $10 million to the Department of Defense Military Burn Research Program (MBRP) to support a research portfolio in the treatment of burns and the trauma associated with burn injuries sustained during combat or combat-related activities. Outcomes of successful research are anticipated to benefit Service members, Veterans, and the general public.  The managing agent for the anticipated Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

The FY20 MBRP Program Announcement and General Application Instructions for the following award mechanism are posted on the Grants.gov website.

The MBRP encourages applications that propose research that advances the development or refinement of interventions, technologies, or knowledge projects that will enable non-medical personnel or medical first responders to provide appropriate burn care closer to the point of injury to enhance the potential for better long-term outcomes. Applications submitted to the FY20 MBRP must address at least one of the following Focus Areas:   

• Burn care solutions for use by non-medical first responders in a Prolonged Field Care (PFC) scenario.
• Burn care solutions for use by the medical first responder in the pre-hospital setting (not necessarily in a PFC scenario).

https://cdmrp.army.mil/funding/mbrp

Clinical Translational Research Award – Preproposal due May 15, 2020

Independent investigators at all academic levels (or equivalent)

• Supports clinical research projects that are likely to have a major impact on therapy by applying promising and well-founded laboratory, pre-clinical, or clinical research findings to the care of the burn-injured patient.
• The proposed study must include clinical research, and may include initial proof of concept trials, studies involving use of human anatomical substances, observational studies, and/or involve some retrospective data analysis.
• Large randomized clinical trials are discouraged.
• Preliminary data is required.
• Animal research is not allowed.

• Pre-application is required; application submission is by invitation only.
• Maximum period of performance is 4 years

• Maximum funding of $1.5 million (M) for total costs (direct costs plus indirect costs)

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcement and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for the award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the MBRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk 
301-682-5507 
help@eBrap.org

The Canada Gairdner Wightman Award recognizes a Canadian health researcher whose career demonstrates extraordinary leadership paired with exceptional science. It is awarded for:

• A sustained career of research excellence in the health sciences at an international level.
• Demonstrated leadership positions and achievements above those of their peers, with local, national and international impact.

Outstanding candidates at varied levels of career development are eligible.

The evaluation of the contributions of the nominees depends heavily on the quality of information supplied. Therefore, nominations should be accurate, detailed, current, complete, and with supporting letters reflecting the nominee’s accomplishments. Letters of support should include national and international representation

The John Dirks Canada Gairdner Global Health Award recognizes the world’s top scientists who have made outstanding achievements in Global Health Research.  Since its inception ago, the Global Health Award has grown significantly to become one of the world’s most prestigious awards recognizing excellence in global health research.

Nominees should be individuals who have made major scientific advances with a significant impact on health outcomes in the developing world. The award is science-focused, and is not intended for those with primarily leadership and administrative accomplishments.

Gairdner invites the scientific community to nominate qualified scientists from any branch of global health. The evaluation of the contributions of the nominees depends heavily on the quality of information supplied. Therefore, nominations should be accurate, detailed, current, complete, and with supporting letters reflecting the nominee’s accomplishments.

SUBMIT A NOMINATION BY JUNE 25, 2019

Purpose

The Governor’s Award provides financial support to academics who are recognized for their expertise and research in areas important to the Bank's core functions.

The award consists of a research grant of $30,000 per year per recipient for a term of up to two years, and is subject to an annual review and confirmation process.

Nomination

There is no limit to the number of candidates a university can nominate for the Governor’s Award.

Eligibility

Governor’s Award nominees are required to:

• be Canadian citizens, permanent residents of Canada, or be otherwise legally permitted to work in Canada
• conduct and support research in Canada (nominations where the preponderance of the research is in Canada could also be considered)
• have obtained a PhD within ten years of their nomination
• be employed by a Canadian university in an associate or assistant professor position during the term of the Award

The Law Foundation of Ontario invites nonprofit organizations to apply for a Justice and technology research grant.

The Foundation wishes to understand how technology is impacting access to justice. Access to justice exists when the public can understand, use, and afford information and services to prevent and resolve their legal disputes and to achieve just outcomes without delay. This granting stream highlights the Foundation’s strategic objective of expanding knowledge: “We continually deepen our knowledge of access to justice, including the contribution of community organizations. We are committed to sharing our knowledge about what is happening and what works.”

The purpose of the Justice and technology research grant is to gain a better understanding of the practical ways in which technology is, or could, potentially change how legal services are provided, and to support access to justice for people with legal needs.

The Foundation understands that there are multiple definitions of “technology” and is open to various research approaches as part of this call.

Eligibility

The Law Foundation of Ontario makes grants to advance access to justice. Grants are made to nonprofit organizations that work to benefit the people of Ontario. The Foundation does not provide funding to individuals or to for-profit ventures.